Vascular tumourBenignICD-10 D18.0

Tufted angioma

Angioblastoma of Nakagawa; progressive capillary haemangioma

Tufted angioma is an uncommon ISSVA benign vascular tumour that sits on a spectrum with its locally aggressive partner kaposiform haemangioendothelioma (KHE) — they share histological features (cannonball / lobular tufts of capillaries) and clinical risk of Kasabach-Merritt phenomenon (consumptive coagulopathy + thrombocytopenia + microangiopathic haemolytic anaemia). Tufted angioma typically presents in infancy / early childhood as a slowly enlarging red-violaceous indurated plaque, often associated with pain, hyperhidrosis and hypertrichosis over the lesion. Symptomatic, progressive or KMP-associated disease should be managed through a specialist vascular-anomalies MDT; systemic sirolimus is the main modern first-line option, with vincristine and corticosteroid-based regimens used as alternatives or adjuncts. Propranolol has a variable response and should not be presented as standard first-line KMP therapy.

CurrentLast reviewed 6 June 2026

Clinical features

  • Slowly enlarging red-violaceous indurated plaque or nodule, typically on the neck, shoulders, upper trunk, thighs.
  • Onset — infancy or early childhood; rarely adult-onset.
  • Often associated features within the lesion:
    • Pain.
    • Hyperhidrosis.
    • Hypertrichosis.
  • Slow expansion; does not involute (contrasts with infantile haemangioma).
  • Kasabach-Merritt phenomenon (KMP) may complicate larger / younger lesions — severe consumptive thrombocytopenia, hypofibrinogenaemia, microangiopathic haemolytic anaemia.

Kasabach-Merritt phenomenon (KMP)

  • Severe consumptive coagulopathy due to platelet trapping within tufted angioma / KHE.
  • Profound thrombocytopenia (often < 10 × 10⁹/L), hypofibrinogenaemia (< 1 g/L), elevated D-dimer, microangiopathic haemolytic anaemia.
  • Tumour enlargement, dramatic deepening of colour, bruising, bleeding.
  • Mortality 20–30% historically; modern outcomes improved with sirolimus.
  • NOT a complication of typical infantile haemangioma — KMP defines KHE / tufted-angioma spectrum.

Histology

  • Discrete lobules ("cannonballs") of capillary tufts scattered through the dermis and subcutis.
  • Sometimes referred to as "lobular capillary tufts in cannonball distribution" — pathognomonic.
  • Endothelial cells, pericytes, surrounding stromal lymphatics positive for D2-40 / podoplanin.
  • Differential — KHE (overlapping features; KHE has more spindled morphology), pyogenic granuloma, infantile haemangioma (GLUT1+).

Management

  • Multidisciplinary vascular-anomalies MDT; specialist tertiary referral for progressive lesions, deep disease or any KMP features.
  • Systemic sirolimus (rapamycin) — main modern first-line option for symptomatic / progressive disease and KMP; substantially improved outcomes since 2010s.
  • Vincristine ± corticosteroids — alternative / adjunctive systemic regimen for KMP; specialist haematology-oncology input.
  • Propranolol — variable response and less reliable than in infantile haemangioma; may be considered only in selected non-KMP cases or under specialist advice.
  • Embolisation — selected large / vascular lesions.
  • Surgical excision — small accessible lesions without KMP.
  • Radiotherapy — historical; carries late-effect risk; rarely used now.
  • Aspirin / pentoxifylline — selected low-grade chronic coagulopathy under specialist direction.

References

  1. Wassef M et al. Vascular anomalies classification — recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics; 2015.
  2. Adams DM et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics; 2016.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.